Tunneled Pleural Catheters for Refractory Effusions Attributed to Congestive Heart Failure (TREAT-CHF) Trial
A legfontosabb adatok
- Ki végzi
- University of California, Los Angeles
- Hol
- Los Angeles (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Visszavonva
- Kezdés
- 2020. okt. 1.
- Befejezés
- 2025. okt. 1.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport nem kap vizsgálati kezelést, összehasonlításként.
- A vizsgált kezelések
- tunneled pleural catheter
- A regiszteradat frissítve
- 2023. április 5.
- Miért állt le
- Lack of enrollment
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 18 feltétel megnézéseKevesebb
Ki vehet részt
- Age > 18 years of age at enrollment
- Able to give consent
- Documented heart failure defined by echocardiography demonstrating depressed left ventricular ejection fraction and/or left ventricular diastolic dysfunction
- Recurrent and symptomatic pleural effusions refractory to medical management
- Maximal medical management will be determined by the referring provider a. This should include use of at least three of the classes of medications that are standard of care for heart failure: i. Angiotensin converting enzyme inhibitor or angiotensin receptor blockers ii. Beta blockers iii. Loop diuretics iv. Potassium-sparing diuretics b. If the patient is not on at least three drugs from the above classes, documentation of drug intolerance must be present
- Documented subjective symptomatic relief after thoracentesis and drainage of the pleural space
- Pleural fluid clinically determined to be due only to CHF
- Pleural fluid analysis consistent with transudate or pseudoexudate a. Transudate: defined by Light's criteria, all of the following must occur, i. Pleural:serum lactate dehydrogenase (LDH) < 0.6 ii. Pleural LDH < 2/3 x upper limit of normal of serum LDH iii. Pleural:serum protein < 0.5 b. Pseudoexudate: defined by all of the following, i. Pleural:serum LDH > 0.6 but < 1 ii. Pleural:serum protein < 0.5 iii. Serum-pleural protein gradient > 3.2 and/or serum-pleural albumin gradient > 1.2
- Anticipated outpatient management
Ki nem vehet részt
- Heart transplant candidate
- Lone right sided heart failure with normal left sided cardiac function
- Active malignancy
- Active pulmonary infection
- Imminent death within 1 month
- Alternate etiology for pleural effusion origin
- On hemodialysis during enrollment
- Exudative pleural effusion, defined as any effusion that dose not meet criteria for transudate or pseudoexudate
- Contraindication for TPC insertion
Helyszínek itt: Egyesült Államok
- UCLA Medical CenterLos Angeles, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
Congestive heart disease (CHF) can frequently cause transudative pleural effusions, some of which do not completely resolve with diuretics alone. These effusions can cause significant morbidity, leading to ongoing dyspnea and hypoxia, resulting in additional office and hospital visits. TREAT-CHF is a randomized trial studying tunneled pleural catheter (TPC) versus standard medical management for the treatment recurrent symptomatic pleural effusions secondary to CHF that are refractory to maximal medical therapy. TREAT-CHF will study whether the addition of a TPC can improve quality of life and minimize health care utilization over the one year following insertion.
A vizsgálat 2 csoportja
- Intervention GroupA vizsgált kezelés
This group will receive placement of a tunneled pleural catheter to drain their recurrent, chronic, and symptomatic pleural effusion in addition to their usual medication therapy.
Kezelés: tunneled pleural catheter
- Usual CareNincs vizsgálati kezelés, összehasonlításként
The control group will continue with medical therapy by their referring physician and serial thoracenteses when clinically appropriate.
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- A regiszteradat frissítve
- 2023. április 5.